Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS-233 SR in Major Depressive Disorder
NCT00092911Phase 3Completed
- Sponsor
- Pfizer
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing DVS-233 SR with Placebo (2 arms). Primary endpoint: Antidepressant efficacy. Status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00092911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092911.